# Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

> **NCT04082260** · — · UNKNOWN · sponsor: **University Hospital Muenster** · enrollment: 150 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab Injection [Lemtrada]

## Key facts

- **NCT ID:** NCT04082260
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082260, "Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04082260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*